The androgen-signaling pathway, mediated through the androgen receptor (AR), is critical in prostate tumorigenesis. However, the precise role of AR in prostate cancer development and progression still remains largely unknown. Specifically, it is unclear whether overexpression of AR is sufficient to induce prostate tumor formation in vivo. Here, we inserted the human AR transgene with a LoxP-stop-loxP (LSL) cassette into the mouse ROSA26 locus, permitting "conditionally" activated AR transgene expression through Cre recombinase-mediated removal of the LSL cassette. By crossing this AR floxed strain with Osr1-cre (odd skipped related) mice, in which the Osr1 promoter activates at E11.5 in urogenital sinus epithelium, we have generated a conditional transgenic line, R26hAR
INTRUDUCTION
Prostate cancer is the most common malignancy among males in the Western world and affects about 2,276,000 men in the United States (http://seer.cancer.gov/statfacts/html/prost.html). Androgen signaling promotes prostate cancer development and progression (1, 2) . Androgens exert their biological effects mainly through the androgen receptor (AR), a member of the steroid hormone receptor superfamily (3) . The AR is expressed in virtually all primary prostate cancers and in most castration-resistant prostate cancers (CRPCs) (4, 5) . AR proteins containing shorter polyglutamine tracts are more transcriptionally active and correlate with an increased risk of developing primary and advanced prostate cancers (6) (7) (8) . Higher testosterone levels and lower levels of sex-steroid binding globulin, which sequesters androgens, also increases the risk of prostate cancer (9, 10) . AR gene amplification appears in almost one-third of prostate cancers after androgen ablation therapy (11, 12) . Global gene expression profiling shows AR as the only gene to be consistently up-regulated in CRPCs (13) .
In the past decade, significant effort has been devoted to generating relevant animal models to characterize the biological significance of the AR-signaling pathway in prostate tumorigenesis. In rat models, administration of testosterone has been shown to increase the expression of AR in prostate epithelium and castration causes downregulation of AR (16) . The effects of selectively increasing AR expression in prostate epithelium have been assessed using transgenic mice. Mice expressing the mouse AR gene driven by the probasin promoter developed focal areas of prostatic intraepithelial neoplasia (PIN) at old age (17) . However, no other proliferative lesions, including overt neoplasia, were observed in this and other similar AR transgenic mouse models. Additionally, only androgen-regulated effects can be evaluated in these mouse models since the expression of the AR transgene was regulated in a ligand-dependent manner. Therefore, there is an urgent need for developing biologically relevant animal models that can mimic the human disease and be used for characterizing the molecular mechanisms underlying CRPCs and for drug development.
In this study, we developed a conditional AR transgenic mouse strain in which the human AR transgene was specifically targeted into the ROSA26 locus (18, 19) . Expression of the AR transgene in this mouse model can be achieved in a constitutive manner through the activation of a Cre recombinase. It has been shown that the mouse Osr1 (odd skipped related) promoter becomes active at E11.5 in urogenital sinus epithelium and maintains its activity in prostatic epithelial cells of prostate glands throughout development (20) . We generated a conditional AR transgenic mouse line (R26hAR LoxP :Osr1-Cre+) by intercrossing the AR floxed mice with Osr1-Cre line. The specific expression of the AR transgene was detected in both luminal and basal epithelial cells of mouse prostatic glands. A total 18 of 40 transgenic mice showed PIN lesions between 6-20 months of age. Most intriguingly, 4 mice developed prostatic adenocarcinomas, 2 of which demonstrated an invasive phenotype. Histological analyses showed specific expression of the human AR transgene in both PIN and adenocarcinomas, providing a link between transgenic AR expression and tumorigenic transformation in the prostate of these transgenic mice. Our data demonstrate that this AR transgenic mouse model is a new and unique strain that can be used to characterize AR action in prostate tumorigenesis and drug development.
EXPERIMENTAL PROCEDURES
Generation of the target vector. The targeting construct used to generate this AR transgenic line, pROSA26-1, is a gift from Dr. Philippe M. Soriano. A loxP-PGK-Neomycin-STOP-loxP cassette was inserted between the CMV early enhancer/chicken β-actin (CAG) promoter and the human AR coding sequence with nine polyglutamine repeats followed by a polyadenylation signal (Fig. 1A) . The targeting construct was linearized by PacI digestion. DNA (25 µg) was electroporated into R1 ES cells as described previously (21, 22) . Correctly targeted ES clones were screened by their acquired puromycin resistance (positive selection), and identified by genomic PCR with P1 (sequence: 5'-TCCTCAGAGAGCCTCGGCTAGGTAG-3') and P2 (seqeuence:5'-TCTGTCTAGGGGTTGGATAAGCCAG-3' ) primers. Southern blot analyses were performed for further confirmation as described previously (18, 23) . In brief, genomic DNA of the ES clones was digested with EcoRV and subjected to Southern blotting with the DNA probe as indicated in Figure 1A .
Mouse breeding, genotyping, and manipulation (castration). The production of chimeras from the ES cells was done as described previously (24) . Progenies were genotyped and male chimeras were identified. Germ line transmission was achieved by backcrossing male chimeras to wild type C57BL/6J females. Daughters carrying the targeted allele were bred to C57BL/6J males. To generate the conditional AR transgenic mice, we intercrossed R26hAR loxP/wt mice with the Osr1-Cre strain, which was kindly provided by Dr. Gail Martin at UCSF and backcrossed more than 7 times with C57BL/6J mice (20) , and PB-Cre4 mice, carrying the Cre transgene under the control of a modified probasin promoter (ARR2PB) (25) . For genotyping, mouse tail tips were incubated in lysis buffer (Cat# 102-T, VIAGEN Biotech, LA, CA) overnight at 55°C, and briefly spun down, genomic DNA was dissolved in TE buffer. Three primers that can distinguish the wild type from the mutant allele were used for genomic PCR amplification. The forward primer, 5'-TCCTCAGAGAGCCTCGGCTAGGTAG-3', was used for both the wild type and targeted alleles, and the reverse primer for the wild type allele was 5'-TCTGTCTAGGGGTTGGATAAGCCAG-3', and for targeted allele was 5'-CCGTAAGTTATGTAACGCGGAACTC-3'. To assess the recombination, the forward primer 5'-TTCGGCTTCTGGCGTGTGAC-3' and the reverse primer 5'-GCTGTGATGATGCGGTAGTC-3' were used in genomic PCR reaction. PCR fragments were amplified at 95°C for 5 min, then 95°C for 45 sec, 63°C for 50 sec, and 72°C for 45 sec for 40 cycles, then 72°C for 5 min.
For castration, either the AR conditional transgenic or control mice were anesthetized by IP injection of Ketamine and Xylazine. Both testicles and epididmides were removed through a scrotal approach. The distal end of the spermatic cord was ligated with silk thread as described previously (26) . All animal experiments performed in this study were approved by the Administrative Panel on Laboratory Animal Care at Stanford University.
Immunohistochemistry, immunofluorescence, and histological analyses. Mouse tissues were fixed in 10% neutral-buffered formalin and processed into paraffin for immunohistochemistry. Samples were cut into 5-µm sections, deparaffinized in xylene, and rehydrated using a decreasing ethanol gradient followed by PBS. Tissues were then blocked with 3% hydrogen peroxide in methanol and protein blocked for 15 min each to inhibit endogenous peroxidase activity and nonspecific antibody binding, respectively. Samples were exposed to a 1:500 dilution of antihuman AR antibody (Santa Cruz Biotechnology, sc-7305), 1:500 dilution of anti-mouse/human AR (Santa Cruz, sc-816, N-20), 1:300 dilution of antip63 antibody (Santa Cruz, sc-8431), 1:3000 of anti Ki67 antibody (Novacastsra, NCL-ki67), 1:300 of E-cadherin antibody (Transduction Laboratories, c20820), 1:800 of CK-5 antibody (Covance, PRB-160P), 1:800 of CK8 antibody (Covance, MMS-162P), 1:200 of synaptophysin antibody (Invitrogen, Z66) in 1% of goat serum at 4°C overnight. Slides were then incubated with biotinylated anti-rabbit or anti-mouse secondary antibody (Vector Laboratories, BA-1000 or BA-9200) for 1hr and horseradish peroxidase streptavidin (Vector Laboratories, SA-5004) for 30 min at room temperature, and then visualized by DAB kit (Vector Laboratories, SK-4100). Slides were subsequently counterstained with 5% (w/v) Harris hematoxylin. For histological analysis, 5-µm serial sections were processed from xylene to water through a decreasing ethanol gradient, stained with hematoxylin and eosin, and processed back to xylene through an increasing ethanol gradient. For immunofluorescence assays, 5-µm sections were boiled in 0.01M citrate buffer (pH 6.0) for 20 mins after re-dehydration from xylene to water, and blocked by 5% goat serum. Tissue sections were then incubated with 1:300 dilution of anti-human AR antibody (Santa Cruz Biotechnology, sc-7305), 1:500 dilution of antimouse/human AR (Santa Cruz, sc-816), or 1:300 dilution of anti-p63 antibody (Santa Cruz, sc-8343) in 1% of goat serum at 4°C overnight. Goat anti-mouse Alexa fluor 594 (Molecular probes, A21203), or goat anti-rabbit Alexa fluor 488 (Molecular probes, A11034) was incubated at 1:1000 dilution for 1 hr at room temperature. Sections were mounted by VECTASHIELD Mounting medium with DAPI (Vector Laboratories, H-1200). Images for all HE and immunohistochemistry experiments in this study were acquired on a Leica dissecting microscope (model MZ9 5 ) using Zeiss Axiovision software. Immunofluorecense images were taken using an Olympus BX-52 microscope.
Immunoprecipitation and Western Blotting.
Mouse tissues were homogenized in ice-cold RIPA buffer (150mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH8.0). Protein concentrations were measured using a protein assay kit (Bio-Rad Laboratories, Cat#: 500-0006). For immunoprecipitation assays, cell lysates containing 150 µg of total protein were diluted in buffer containing 20 mM HEPES (pH8.0), 0.5% NP-40, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl2, 1 mM CaCl2, 10 mM ZnCl2, 1 mM DTT, 1 mM PMSF, 5 mg/ml Leupeptin, and 5% glycerol and then incubated with rabbit normal IgG or anti-FLAG antibody conjugated with pre-equilibrated Protein-A Sepharose beads at 4°C with gentle rotation for 7 hours. The beads were collected by centrifugation, and gently washed 3 times with the same buffer as described above. Equal amounts of immunoprecipitates were eluted using 2x sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 20% (v/v) glycerol, 0.004% bromphenol blue) and analyzed by Western blot. A 1:500 dilution of a monoclonal antibody against the human AR (Santa Cruz Biotech, Cat No: sc-7305) was used. Protein detection was performed using ECL kit according to the manufacturer's protocol (Amersham Biosciences).
Cell cultures and transient transfections.
The monkey kidney cell line, CV-1, was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum (FCS) (HyClone, Denver, CO). Transient transfections were carried out using a Lipofectamine transfection kit (Invitrogen, Carlsbad, CA). Transfection and whole cell collection were performed as described previously (27, 28) . Whole cell lysates were prepared from transfected cells and subjected to Western blot analyses.
Statistical analyses.
We presented the data as the mean ±SD. We made comparisons between groups, using a two-sided Student's t test. P<0.05 and P<0.01 were considered significant.
RESULTS
Generation of the AR conditional transgenic mice. Previous AR transgenic mouse models were developed through random insertion transgenesis in ES cells or pronuclear microinjection (17) . To achieve high targeting efficiency and comparable expression of the AR transgene between animals, we developed a "floxed" AR allele in which the human AR transgene containing a short polyglutamine repeat tract was targeted into the ROSA26 locus (18, 19) . A loxP flanked transcriptional silencing element was inserted between the CAG promoter, a hybrid CMV enhancer coupled to a modified chicken β-actin promoter, and the AR coding sequence in the targeting vector (Fig. 1A) . Since the CAG promoter is ubiquitously active in most mouse tissues in vivo (29) , AR transgene expression in this mouse model can be achieved in a constitutive but tissue specific manner through Cre-recombinasemediated removal of the LSL cassette. Thus, this mouse model will enable us to characterize the specific role of AR in prostate tissues in a ligandindependent manner to avoid the complication observed in previous mouse models regulated by androgen-induced promoters. AR transgene expression was assessed in CV-1 cells through recombinase-mediated removal of the transcriptional silencer, the LSL cassette. Expression of FLAG-tagged AR was observed in the cells co-transfected with the targeted vector and CMV-Cre plasmids (Fig. 1B) . Genomic DNA samples were isolated from ES cells and digested with EcoRV and subjected to Southern blot analyses (18, 23) . Four positive clones displayed an 11.5 kb hybridization band corresponding to the wild-type locus and a 3.8-kb band that represents the targeted ROSA26 locus (Fig. 1C) . Two independent positive ES cell clones were injected into C57BL/6J blastocysts that were then implanted into pseudopregnant recipients to create chimeric animals.
Conditional expression of the AR transgene in mouse prostatic epithelium. The Osr1-Cre mouse line is a newly established tool strain, in which the Osr1 promoter activates at E11.5 in urogenital sinus epithelium and retains its activity in epithelium of the prostate throughout development (20) . Although the activity of the Osr1 promoter is not fully restricted to the prostate gland, its early activation in prostatic epithelial cells makes Osr1-Cre a unique tool in assessing AR action in prostate development and tumorigenesis. We crossed the floxed AR strain with Osr1-Cre mice to generate both Figure 1) . In contrast, only a 1.6 Kb non-recombined fragment was observed in mouse tissues isolated from age matched R26hAR loxP/wt :Osr1-Cre-controls. To confirm the expression of transgenic human AR protein in the mice through LoxP/Cre recombination, we then analyzed different mouse tissues using immunoprecipitation and immunoblotting. As shown in Figure 1D , Flag tagged human AR proteins were detected in the prostate gland, bladder, and heart of 4-week-old R26hAR (Fig. 3A1 versus 3B1) . We then used immunofluorescence to co-localize both human AR and endogenous mouse AR in the above mouse tissues. A uniform nuclear immunofluorescence signal was observed with the antibody (N20) against human and mouse AR proteins in the prostate of R26hAR loxP/wt :Osr1-Cre+ mice (green, Fig. 3C2 ), but only a portion of prostatic epithelial cells showed a positive immunofluorescence with the human AR antibody (red, Fig. 3C1) . A significant amount of overlay was observed especially in luminal epithelial cells with these two antibodies (arrows, Fig. 3C3 ). Interestingly, positive staining of the human AR protein also appeared in prostatic basal cells in the AR transgenic mice.
As described above, we observed positive AR immunostaining in both prostatic luminal and basal epithelial cells of R26hAR loxP/wt :Osr1-Cre+ mice (Fig. 3C) . It has been suggested that prostatic basal cells may contain prostate "stem" or "progenitor" cells (30, 31) . We then used an antibody against p63, a prostatic basal cell marker, to confirm the expression of the AR transgene in prostatic basal epithelial cells (32 ;PBCre4+ mice (Fig. 3D2, 3D5, 4A , B, M, P, and S), DP (Fig. 4G) , and VP (Fig.  4J) . The fibromuscular stroma was intact and the glandular and duct profiles were undisturbed ( Fig.  4G and J) . In Figure 4M , P, and S, the foci of atypical cells partially fill the lumen of the ducts. Intraluminal glands forming within the original glands in the dysplastic lesions are pronounced in these cases, which are further characterized by epithelial cell crowding, and enlarged vesicular nuclei that often contained one or more prominent nucleoli (Fig. 4N, Q, and T) . Using the antibody against the human AR protein (440), we detected positive immunostaining of transgenic AR in almost all atypical cells within mPIN lesions (Fig.  4C, F (Fig. 5A and 5B), the neoplasms were grossly evident, being large, extensive tumor masses in the pelvis (Fig.  5A1) . The tumors were poorly circumscribed and unencapsulated ( Fig. 5A2 and 5B1) , and comprised of haphazard acini and lobules of pleomorphic cells (Fig. 5A4, 5A5, 5B3 ) with no or limited amounts of fibrovascular stroma. Tumor necrosis was also noted in one of the tumors (Fig.  5B2) . In both, malignancy was evident (in addition to the architectural, cellular and nuclear features) by obvious vascular invasion by neoplastic cells (Fig. 5A3 and 5A6 ), or local invasion of the tumor beyond the basement membrane into surrounding stromal tissues that show an early desmoplastic response (Fig. 5B4) . In the other two mice (Fig. 5C and 5D ), smaller prostatic adenocarcinomas were noted by microscopic evaluation only. Specifically, the tumors were discrete, circumscribed unencapsulated masses comprised of haphazard solid epithelial sheets (with only rare glandular formation) of pleomorphic cells with scant fibrovascular stroma. Although neither obvious local nor vascular invasion was noted in these tumors, the architectural, cellular and nuclear features of neoplasms suggest malignant neoplastic transformation of prostatic epithelial cells. Despite extreme attention to the presence of metastases in distant organs in the mice showing prostatic adenocarcinomas, distant dissemination of neoplastic prostatic epithelial cells was not noted in all four mice.
Conditional expression of the human AR transgene induces prostatic cell proliferation and contributes to development of adenocarcinomas.
A promotional role of AR in cell proliferation has been demonstrated previously (1, 33, 34) . To understand the cellular effects resulting by conditional expression of the AR transgene in the mouse prostate, we assessed for proliferation using Ki67 immunohistochemistry in three mice from each genotype. A significant increase in Ki67 immunostaining in both mPIN and prostatic adenocarcinoma lesions was observed when compared to wild-type samples (Fig. 6A-I ). Ki67 immunostaining was quantified by counting a total of 1000 epithelial cells from five high-power fields in each sample. Experiments were repeated three times and three different slides prepared independently from three mice in each genotype were analyzed. Representative data were shown that the epithelial proliferative index increased from 10 in wild-type cells to 50 in mPIN lesions and 140 in prostatic adenocarcinoma lesions (Fig.  6J ). These results demonstrate a tumor-promoting role of the AR human transgene expression in the mouse prostate of the transgenic mice.
In prostatic epithelium there are basal and luminal epithelial cells as well as neuroendocrine cells. Development of both adenocarcinoma and neuroendocrine carcinoma in mouse prostates has been demonstrated in previous animal models (35) (36) (37) . To further define the origin of tumors in these AR transgenic mice, we performed comprehensive immunohistochemical analyses to examine a series of prostatic cellular markers. As shown in Figure  7 , prostatic tumor cells showed positive immunostaining with the human AR antibody (Fig. 7D-F) , suggesting a direct link between expression of transgenic human AR and oncogenic transformation in the mice. The tumor cells also showed positive staining for E-cadherin and CK8 (Fig. 7G-L) , the hallmarks of secretory epithelium, but no staining for the neuroendocrine cell marker synaptophysin (Fig. 7S-V) . Interestingly, staining of p63 and CK5 was also observed in some tumor cells in one of the R26hAR loxP/wt :Osr1-Cre+ mice (Fig. 7N & Q) , suggesting the possibility that prostatic basal epithelial cells may also be tumor initiation cells in this animal model.
DISCUSSION
The androgen-signaling pathway plays a key role in prostate cancer initiation and progression. The pioneering work of Charles Huggins and Clarence Hodges demonstrated that depletion of androgens resulted in significant regression of prostate tumors, heralding the now ubiquitous and most effective strategyto treat prostate cancer, androgen deprivation therapy (38) . The fundamental premise of this therapy has remained almost unchanged since then, despite different medications that have been developed and applied to patients for the purpose of reducing the level of androgens or competitively repressing AR function. Most patients develop hormone refractory tumors within two to three years following initiation of therapy, for which there is no effective treatment. One of the main reasons for the limited progress is the lack of biologically relevant animal models that mimic the human disease and can be used to investigate AR action in androgen-induced prostate tumor initiation and disease progression.
In past years many genetically-modified by guest on November 7, 2017 http://www.jbc.org/ Downloaded from mouse (GEM) models have been established for studying prostate tumorigenesis. They involve either overexpression of oncogenes or targeted deletion of tumor suppressors in the prostatic epithelium. Transgenic (gain-of-function) models that express SV40 T antigen (i.e., the TRAMP and LADY models) and c-Myc have been developed previously (39) (40) (41) . Knockout mice with specific deletion of various tumor suppressors in the prostate have also been developed (39, (42) (43) (44) . One of the best characterized mouse models is the conditional pten knockout (37) . Loss of both alleles of pten results in invasive prostate cancer that metastasizes to lymph nodes and lung in some mice (37) . Combining PTEN loss with other genetic abnormalities has led to several additional mouse models (45) (46) (47) . Deletion of Nkx3.1 and PTEN results in androgen-independent prostate cancer (39, 47) . However, despite the progress offered by these GEM models in analyses of different molecules and signaling pathways in prostate tumorigenesis, there is a great need for new animal models for characterizing the androgen-axis, a key pathway, in prostate development and tumorigenesis.
In this study we report a new AR conditional transgenic mouse model, R26hAR loxP :Osr1-Cre+. In this mouse model expression of the human AR transgene is regulated in a constitutive but prostate specific manner by the hybrid CAG promoter coupled CMV enhancer and chicken β-actin promoter through loxP/Cre recombination. We used newly established Osr1-Cre mice to activate AR transgene expression. The Osr1 promoter is active at E11.5 in urogenital sinus epithelium and maintains its activity in prostatic epithelial cells throughout development (20) . We detected transgenic AR expression in both luminal and basal epithelial cells of prostatic glands of 4-week-old R26hAR loxP :Osr1-Cre+ mice. The robust activity of the Osr1 promoter is detected in all four prostatic lobes though it is not fully restricted to the prostate as described previously (20) . Through loxP/Cre mediated recombination, deletion of the LSL cassette resulted in the activation of the AR transgene expression in a constitutive manner. These unique and novel features distinguish our AR transgenic mice from other GEM models, which should allow us to assess and validate the AR action in both prostatic luminal and basal epithelial cells and in a ligand-dependent or -independent manner.
The majority of human primary prostate cancers are androgen dependent. Data from previous AR transgenic mouse models also showed that overexpression of the mouse AR transgene in prostate luminal epithelial cells promotes proliferation of the epithelium, with the subsequent development of pre-cancerous lesions and mouse PIN in aged mice. However, the precise role of AR in promoting prostate cancer development still remains unclear. In this study, we showed that almost half of loxP/loxed ;PB-Cre+ mice, in which the AR transgene expression was selectively targeted in prostatic luminal epithelial cells through ARR2PB promoter (25) . We only observed mPIN lesions but no prostatic adenocarcinomas in those mice. These results are consistent with the previous studies and implicate that selective activation of the AR transgene expression in different cells of the prostate may regulate cell proliferation distinctly during the course of mouse prostate cancer development.
The promoting role of AR in stimulating prostatic cell growth has been implicated in human prostate tumorigenesis. However, it is unclear whether increasing AR expression, a steroid hormone receptor, is sufficient to induce prostate cancer development in mice since previous AR transgenic mice only showed mPIN lesions (17) . Thus, the finding in this study is very interesting and suggests that this mouse model is novel and should be characterized further. In this mouse model, positive immunostaining of transgenic human AR protein appears in the majority of atypical cells in mPIN lesions and tumor cells of prostatic adenocarcinomas, providing a direct link between AR transgene expression and oncogenic transformation in mouse prostates. In addition, an increase of Ki67 positive cells has been observed in all above prostatic adenocarcinoma and PIN samples. In this study we also examined cell apoptosis in the above samples with mPIN and adenocarcinoma lesions and did not observe any significant changes. These data further support a promotional role of transgenic AR protein in inducing prostatic epithelial proliferation.
Using immunohistochemistry, we observed that most tumor cells in the adenocarcinoma and PIN lesions were E-cadherin and CK8 positive but synaptophysin negative. These data suggest that tumor cells are immunoreactive to luminal epithelial cellular markers. Interestingly, we also observed some immunolabeling with p63 and CK5 antibodies in some tumor cells from one R26hAR (30, 31) . In general, most prostatic basal epithelial cells have no or low expression of the AR. Enforcement of transgenic AR expression in basal cells may disrupt the normal differentiation pathway and induce oncogenic transformation. Although it is unclear whether activation of the AR transgene through Osr1-Cre can directly promote and induce normal basal epithelial cells into "primary" tumor initiating cells, occurrence of prostate adenocarcinomas in this AR transgenic mouse model provides a direct line of evidence that dysregulation of the AR signaling pathway can promote prostate tumor formation in mice. Interestingly, we only observed prostatic adenocarcinomas in about 10% of the transgenic mice that have been examined in this study. The low penetrance of adenocarcinoma in this model further implies that other additional "hits" may be required to enhance AR-mediated oncogenic transformation in prostate tumorigenesis. Thus, the current AR transgenic mouse model mimics features of the human disease and can be used to identify other factors and pathways that promote AR action in inducing prostate cancer initiation and progression.
The probasin promoter has been widely used to create prostate GEM models in the past. It is activated postnatally in an androgen-inducible manner and is targeted selectively to luminal cells (25) . One of the most important features for our AR conditional transgenic mouse model is that AR expression is regulated in a constitutive but prostate specific manner by the hybrid CAG promoter through loxP/Cre recombination (Fig.  1A) . In this study, we compared expression of the AR transgene between castrated versus uncastrated R26hAR Figure 2) . Thus, this model allows us to characterize the role of AR in the absence of androgens. Further studies with larger cohorts of the AR transgenic mice will allow us to fully assess the effect of castration in growth and progression of prostatic adenocarcinomas in this new mouse model. tissues (A, D, and G), or tissues containing mPIN (B, E, and H) or adenocarcinomas (C, F, and I) were isolated from the AR conditional transgenic mice or controls and assessed for cell proliferation. All tissues were stained with a Ki67 antibody and the proliferation indexes for the above tissues were measured in total 1000 epithelial cells counted from five high-power fields. Experiments are repeated three times and three different slides prepared independently from three mice in each genotypy
